Lates News

Rongchang Bio (688331.SH) stated at the performance briefing that the company has reached a global exclusive license agreement with Seattle Genetics, Inc. (now acquired by Pfizer Inc.) in 2021. The company has granted the global development and commercialization rights of vedolizumab (code: RC48) in the Rongchang Bio region (i.e. all Asian regions except Japan and Singapore) outside of its territory. Currently, Pfizer is progressing overseas clinical trials of RC48 according to plan. The main challenges faced in the internationalization process include differences in regulatory environments in different countries and regions, the complexity of market access policies, and the dynamic changes in the competitive environment. The company is actively collaborating closely with Pfizer to provide necessary support and data to facilitate clinical development and application in overseas markets.